Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Dare Bioscience Inc DARE

Healthcare Biotechnology
Dare Bioscience, Inc. is a biopharmaceutical company. The Company's programs target unmet needs in women's health, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Its product includes XACIATO (clindamycin phosphate) vaginal gel 2%. XACIATO is a single-dose prescription medication for the treatment of bacterial... see more

Recent & Breaking News (NDAQ:DARE)

Daré Bioscience to Participate in Three February Conferences

GlobeNewswire February 1, 2023

Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1 Trial of DARE-HRT1 that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy for both Vasomotor and Vaginal Symptoms of Menopause

GlobeNewswire January 26, 2023

Daré Bioscience Announces Positive Pharmacokinetic (PK) Results from the DARE-HRT1 Phase 1 / 2 Study that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy for both Vasomotor and Vaginal Symptoms of Menopause

GlobeNewswire January 9, 2023

Daré Bioscience Announces New Development Program, DARE-PDM1, as a Potential First-in-Category Treatment for Primary Dysmenorrhea

GlobeNewswire December 12, 2022

Daré Bioscience Announces Grant to Develop Novel Hydrogel Formulation for Delivery of Live Biotherapeutics to Support Vaginal Health

GlobeNewswire November 15, 2022

Daré Bioscience Announces Positive Topline Results from DARE-VVA1 Phase 1/2 Clinical Study

GlobeNewswire November 14, 2022

Daré Bioscience Reports Third Quarter 2022 Financial Results and Provides a Company Update

GlobeNewswire November 10, 2022

Daré Bioscience to Present at the Stifel 2022 Healthcare Conference

GlobeNewswire November 8, 2022

Daré Bioscience to Host Third Quarter 2022 Financial Results and Company Update Conference Call and Webcast on November 10, 2022

GlobeNewswire November 3, 2022

Daré Bioscience Announces Subject Screening for Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder Complete

GlobeNewswire November 1, 2022

Daré Bioscience Announces Positive Efficacy Results from the DARE-HRT1 Phase 1 / 2 Study

GlobeNewswire October 17, 2022

Daré Bioscience Announces IDE Approval for a Single Arm, Open-Label Pivotal Contraceptive Efficacy Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal Contraceptive

GlobeNewswire October 10, 2022

Daré Bioscience to Participate in Two Upcoming Conferences

GlobeNewswire September 15, 2022

Daré Bioscience to Participate in H.C. Wainwright 24th Annual Global Investment Conference

GlobeNewswire September 6, 2022

Daré Bioscience Announces Interim Analysis of Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder

GlobeNewswire August 29, 2022

Daré Bioscience, Inc. Announces Global Licensing Rights to the Novel Antimicrobial Glycerol Monolaurate for Vaginal Health

GlobeNewswire August 24, 2022

Daré Bioscience Reports Second Quarter 2022 Financial Results and Provides a Company Update

GlobeNewswire August 9, 2022

Daré Bioscience to Host Second Quarter 2022 Financial Results and Company Update Conference Call and Webcast on August 9, 2022

GlobeNewswire August 2, 2022

Daré Bioscience to Participate in Maxim Group Women's Health Panel

GlobeNewswire July 7, 2022

Daré Bioscience Announces Closing of Global License Agreement with Organon to Commercialize XACIATO(TM) (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis

GlobeNewswire June 30, 2022